Objectives: The objective of this study was to evaluate the evolution and risk factors of ESBL-producing Enterobacteriaceae (ESBL-E) carriage in children in the community for a long period distinguishing ST131 and non-ST131 Escherichia coli.
Introduction
In the past decade, the emergence of ESBL-producing Enterobacteriaceae (ESBL-E), both in nosocomial and community settings, has been one of the most concerning epidemiologic changes in infectious diseases. Carriage of ESBL-producing isolates in the gut flora may serve as a reservoir of resistance genes and has been associated with a high risk for infection caused by ESBL producers. 1 Among Enterobacteriaceae, Escherichia coli is becoming the most important species implicated in both community-onset and hospital-associated infections on a global scale. 2, 3 ESBL genes are spreading rapidly due to the combined expansion of mobile genetic elements and clonal dissemination. They are frequently accompanied by genes encoding resistance to various antibiotic groups, such as aminoglycosides, fluoroquinolones or sulphonamides, which leaves few treatment options. The best example of antibiotic resistance spread is E. coli ST131, an MDR clonal group disseminated worldwide. This clonal group has contributed to the dissemination of highly efficient resistance to third-generation cephalosporins because of the bla CTX-M-15 gene and is associated with fluoroquinolone resistance, which explains in part the rapid increase in prevalence of antimicrobial resistance in E. coli. 4, 5 The rate of faecal carriage of ESBL-E has mainly been investigated in nosocomial outbreaks, in traveller adult patients or in children attending daycare centres; few studies have evaluated intestinal carriage in children in the community. In a preliminary study of this issue, we showed that between October 2010 and June 2011, faecal carriage of ESBL-E was 4.6% and was mainly associated with the use of third-generation oral cephalosporins. 6 The aim of this study was to investigate for a longer period (2010 -15) the evolution in prevalence and the risk factors of community-acquired ESBL-E in microbiota of children aged 6 -24 months. The rate of ST131 carriage, phenotypic resistance patterns and the genetic characteristics of ESBL-producing E. coli were also investigated.
Methods

Participants
Between October 2010 and June 2015, 18 French paediatricians located in three regions (Ile de France, Lorraine and Provence-Alpes-Cô te d'Azur) took part in this prospective study. A rectal sample was obtained from children aged 6 -24 months during routine check-ups with normal findings or when they presented with acute otitis media. This work was an ancillary study of the French nasopharyngeal carriage study performed by ACTIV, a paediatric research network. 7, 8 The exclusion criteria were antibiotic treatment within 7 days before enrolment and severe underlying disease. Once written informed consent had been obtained, we queried the parents or guardians about the child's demographics and risk factors for carriage of resistant bacteria, including use of any antibiotics (between 7 days to 3 months before enrolment), daycare attendance modality, premature birth or caesarean birth, any siblings, previous hospitalization (during the previous 6 months and since birth), travel history and geographical areas visited in the last 6 months.
Ethics
The study was approved by the Saint Germain en Laye Hospital Ethics Committee (10/10/2010-CPP06063). Written informed consent from parents or guardians was obtained.
Microbiology investigations and genetic characterization
On inclusion, rectal samples were taken using a flexible, sterile, soft rayon swab tip. After sampling, the swabs were immediately inoculated in transport medium (Copan, Brescia, Italy) at room temperature and sent within 48 h to the E. coli National Reference Centre-associated laboratory at Robert Debré Hospital, Paris. The rectal swabs were spread on ChromID ESBL screening medium to screen stool flora for cefpodoxime-resistant Enterobacteriaceae (bioMérieux, La Balme-les-Grottes, France).
One colony of each morphological type growing on the medium was identified using the API20E system (bioMé rieux, Marcy-l'É toile, France) (2010 -14) and then with the Bruker Biotyper matrix-assisted laser desorption ionization -time of flight mass spectrometer (2014 -15). Antibiotic susceptibility was determined using the disc diffusion method on Mueller-Hinton agar and interpreted as specified by EUCAST (http://eucast.org/). Possible evidence of ESBL production was defined as synergy between clavulanic acid and at least one of the extended-spectrum cephalosporins (ceftazidime, cefotaxime or cefepime) or aztreonam.
Multiplex PCR was used to characterize b-lactamase genes (including bla CTX-M , bla SHV , bla TEM and bla OXA-1 ) with previously described methods and primers. 9 Nucleotide sequences obtained were aligned with GenBank reference sequences by using ClustalX within BioEdit v7.0.5.3 and compared with published sequences in the Lahey database (http://www.lahey.org/ studies). Clonal relationships among E. coli isolates were identified by semiautomated rep-PCR (DiversiLab; bioMérieux, Marcy-l'Étoile, France). 10 The clonal group ST131 was identified by using DiversiLab as described previously, 11, 12 with the ST131 strain S242 as a control. 13 On B2 strains, we also did allele-specific PCR confirmation of the pabB and trpA alleles to detect those belonging to the pandemic clone O25b-ST131 and used a specific PCR-based method to detect the O16-ST131 clade and to distinguish it from the O25b-ST131 subset. 14, 15 On isolates belonging to the ST131 clonal group, we amplified and sequenced the fimH allele as previously described. 16 Sequences were analysed using BioEdit software using ECOR strains' sequences as references, which was sufficient to determine all H types. 17 Strains were assigned to one of the E. coli phylogenetic groups (A, B1, B2, C, D, E and F) 18 or phylogenetic subgroup B2 1 , by using a previously described multiplex PCR-based method. 19 A PCR-based method was used to screen the strains for 11 genes encoding the following putative virulence factors: fyuA, yersiniabactin; hly, haemolysin; sfa/foc, S or F1C fimbriae; papC, P fimbriae; iucC, aerobactin; papG (II and III alleles), P fimbriae adhesins; cnf1, cytotoxic necrotizing factor; iroN, salmochelin; ibeA, invasin; and hra, heat-resistant agglutinin. 20 
Study groups and statistical analyses
Data were double-entered by using 4D software v12 and analysed by using Stata/SE 13.1 (StataCorp, College Station, TX, USA). Trend tests involved the Cuzick test. The x 2 test was used in univariate analysis to identify potential factors (P, 0.2) to be included in multivariate models. Then, we used a logistic regression model, computing ORs and 95% CI, to identify risk factors associated with ESBL-E, ST131 and non-ST131 carriage. Data for travel history were available since 2012. Countries visited were grouped into four geographical regions: African/Mediterranean region (including Algeria, Morocco, Tunisia, African countries, Greece, Croatia, Spain, Portugal, Israel, Italy and Turkey), America, Asia/Oceania and western/northern Europe. When several countries were visited, the longest stay was selected. Children who had not travelled were grouped with western/northern Europe. To analyse the evolution of ESBL carriage, we distinguished five periods: period 1, October 2010 -June 2011; period 2, October 2011 -June 2012; period 3, October 2012-June 2013; period 4, October 2013-June 2014; and period 5, October 2014 -June 2015.
Results
Global results
ESBL carriage was assessed in 1886 children. The mean age was 13.3+5.2 months, and 880 (46.7%) were between 6 and 12 months old. The sex ratio was 1.17 (male/female). Overall, 41.9% of the children attended daycare centres, and 30.5% and 27.6% were cared for by a child minder and at home, respectively. In all, 29.6% (362 of 1221) had travelled and 38.2% received antibiotics within 7 days to 3 months before enrolment. Details of geographical regions and antibiotic treatments are in Table 1 .
ESBL-E were found in 144 patients (7.6%). Evolution of ESBL carriage by year is shown in Figure 1 , increasing from 4.8% (95% CI ¼ 2.9 -7.3) to 10.2% (95% CI ¼ 7.5 -13.5) from period 1 to period 5, respectively. ESBL-producing E. coli was found in 142 patients (98.6%); 12 patients harboured 2 different strains of ESBL-producing E. coli and 6 a strain of ESBL-producing E. coli and another Enterobacteriaceae species (4 Citrobacter sp., 1 Enterobacter asburiae and 1 Leclercia sp.). Two patients carried only an ESBL-producing Klebsiella pneumoniae strain. We isolated 162 ESBL-E, including 154 E. coli.
Among these 162 isolates, the activity of trimethoprim/ sulfamethoxazole and fluoroquinolones was severely compromised, with 54.3% and 36.4% of isolates showing resistance. Resistance to aminoglycosides was 14.8% and 3.7% for gentamicin and amikacin, respectively. Overall, 22.9% were resistant to both trimethoprim/sulfamethoxazole and ciprofloxacin. All isolates were susceptible to imipenem and ertapenem.
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In total, 160 ESBL isolates were typeable and most harboured the CTX-M type (144 of 160; 90%). The most prevalent variants (.5%) were bla CTX-M-1 , bla CTX-M-15 , bla CTX-M-14 , bla CTX-M-27 and bla SHV-12 , at 32.5%, 21.3%, 19.4%, 13.8% and 6.9%, respectively, over the whole period. The most significant decline was for bla CTX-M-1 , which represented 40.9% of bla CTX-M in period 1 and decreased to 18.8% in period 5. In contrast, the most important progression concerned bla CTX-M-27 (from 4.5% to 25% between period 1 and period 5). These evolutions were statistically significant (P trend ¼ 0.036 and P trend ¼ 0.006, respectively). The prevalence of the variants bla CTX-M-14 and bla CTX-M-15 was quite stable over time ( Figure 2 ).
Regarding the ESBL-producing E. coli, 150 isolates could be affiliated with a phylogenetic group. Over the whole study period, each phylogenetic group included at least 5% of the isolates, with B2 the leading group, representing one-third of the isolates (Figure 3 ). Of note, only one isolate, in 2015, belonged to the highly virulent B2 1 phylogenetic subgroup. Over the study period, the main evolution of note was the increase in prevalence in the B2 group, particularly in period 5, representing nearly half (48%) of the ESBL-producing E. coli, as compared with 5% in period 1 (Figure 3 
ESBL-producing ST131 isolates
Semi-automated rep-PCR analysis (DiversiLab; bioMé rieux, Marcy-l'Étoile, France) easily identified isolates belonging to the clonal group ST131, which were closely related to the ST131 control strain S242 (.95% similarity). These results were confirmed using specific PCR methods. 14, 15 We found a high level of genomic diversity for the 112 non-ST131 isolates because distinct clonal groups (strains sharing .95% similarity) contained no more than four isolates (Figure S1, available as Supplementary data at JAC Online).
Clonal group ST131 was found in 25.8% (39 of 151) of ESBL-producing E. coli isolates from 2010 to 2015, ranging from 5.0% in period 1 (only 1 of 20 isolates) to 37% in period 5 (Figure 4 ). Among these, 30 (77%) belonged to the O25b subgroup and 9 (23%) to the O16 subgroup. Regarding fimH alleles, all O25b-ST131 isolates contained fimH30 except one with a single locus variant of fimH30 and all O16-ST131 isolates contained fimH41 except one with a single locus variant of fimH41. Results of the resistance of isolates belonging to the clonal group ST131 are depicted in Table 2 . Of note, ciprofloxacin resistance was found in 100% of O25b-ST131 isolates, whereas only 33% of the O16-ST131 were resistant.
The four major ESBL variants among the ST131 clonal group were CTX-M-1 (10.3%), CTX-M-14 (12.8%), CTX-M-15 (30.8%) and CTX-M-27 (41%). For ST131 strains, the most prevalent virulence genes were fyuA (100%) and iucC (95%); all other virulence genes were present in ,15% of the strains.
On multivariate analysis to identify specific risk factors associated with carriage of ST131-ESBL-producing compared with non-ESBL-producing strains, history of hospitalization was the only risk factor identified (aOR¼3.5, 95% CI¼1.4-8.8, P¼0.007).
On multivariate analysis comparing carriage of non-ST131-ESBLproducing and non-ESBL-producing strains, risk factors identified were children cared for at home (aOR ¼ 1.9, 95% CI ¼ 1.1 -3.2, P ¼ 0.02), travel history (aOR ¼ 2.0, 95% CI ¼ 1.2 -3.2, P ¼ 0.008) and recent use of oral third-generation cephalosporins (aOR 2.3, 95% CI ¼ 1.1 -4.8, P ¼ 0.021). The risk of carrying ST131-ESBLproducing compared with non-ST131-ESBL-producing strains was strongly associated with hospitalization in the last 6 months (aOR¼10.6, 95% CI¼2.0-55.7, P¼0.005).
Discussion
In the community, faecal carriage of ESBL-E in children in industrialized countries has been rarely reported. The few studies focusing on this problem have been limited in time, geographical region or associated risk factors. Here, we report one of the largest cohorts exhibiting evolution in carriage over a 5 year period, the risk factors and molecular epidemiology of community-acquired ESBL Enterobacteriaceae in infants.
In Europe, in 2010, a Swedish study found a community carriage rate of 2.9% (313 stool specimens) in healthy preschool children. 21 In 2012, a French study reported a 6.7% carriage rate (28 of 419) in daycare centres. 22 This rate is similar to the 6.9% Birgy et al.
(31 of 452) we found for the same year. A 2014 publication from northern Spain reported a 24% carriage rate (30 of 125) in healthy children. 5 In our longitudinal study, we confirmed the gradual increase in carriage of ESBL-E mainly due to E. coli in the community.
As expected, we observed that E. coli was the Enterobacteriaceae species most prone to harbour ESBL genes, of which the CTX-M types predominated. CTX-M-1, CTX-M-15 and CTX-M-14 were the most prevalent enzymes, which agrees with previous reports. 23, 24 However, we observed a high increase in prevalence of the CTX-M-27 enzyme. In a recent longitudinal Japanese study, CTX-M-27 was not present in 2005, but represented .50% of the CTX-M alleles in 2011 -12. 25 A high proportion of CTX-M-27 has been also reported in different countries. 26, 27 Among all our ESBL-producing strains, 80% (16 of 20) of the CTX-M-27 type belonged to the ST131 clonal group. A similar high rate was noted by Matsumura et al. 25 Therefore, this clonal group may be responsible for the increasing prevalence of CTX-M-27.
Genotyping characterization of our ESBL-producing E. coli isolates revealed all phylogenetic groups featuring this mechanism of resistance. As well, we observed high genomic diversity of isolates not belonging to the ST131 clonal groups (found on rep-PCR, DiversiLab), which clearly demonstrates the high capacity for spread of ESBL, particularly CTX-M genes, among different genetic backgrounds. However, the major highly virulent phylogenetic subgroup B2 1 corresponding to ST95 still exceptionally featured this resistance mechanism. 28 To understand better the diffusion of ESBL-producing strains, factors affecting the emergence or evolution of ESBL-E should be identified. In our global analysis, we found three factors significantly associated with increased prevalence of carriage of 29 These high rates of travel acquisition suggest a high prevalence of ESBL-E faecal carriage in southern countries and is corroborated by several studies identifying 23% -64% of children carrying ESBLproducing bacteria in community settings in non-industrialized countries. 30, 31 Another factor associated with ESBL-E carriage was children cared for at home. This surprising result agrees with a recent study from Spain, finding that children not attending a nursery school had the highest rate of ESBL carriage, 5 but disagrees with findings from an older European study. 21 One possible hypothesis is that children in contact with other children could have more chance of renewing their intestinal flora with interpersonal and interchildren contacts and thus more chance of exchanging their ESBL-producing strains for susceptible strains. This renewing of the microbiota is less likely to occur in children cared for at home, who are in contact with only their parents or siblings, particularly if family contacts may also carry resistant strains (particularly travellers). Moreover, intra-family spread of ESBL-E has been reported previously. 32 A final factor associated with ESBL-E carriage was antibiotic use in the previous 3 months. In our previous study (2010 -11), risk of ESBL carriage was associated with recent use of oral thirdgeneration cephalosporins. 6 The French recommendations for acute otitis media treatment changed at the end of 2011. 33 Since then, amoxicillin has become the first-choice treatment and use of oral third-generation cephalosporin concomitantly decreased, from 33% in 2010 to 5% at the end of 2012. 34 The major modification of types of antibiotics prescribed may explain in part the decrease in ESBL carriage between period 2 and period 3 in our study. However, the potential beneficial effect was transient, and the proportion of ESBL carriers increased between the last two periods of the study. Finally, carriage of ST131 strains, not associated with antibiotic use and that predominated during the last period, may explain the re-ascent of carriage of ESBLproducing strains.
The clonal group ST131 represented 25.8% of the ESBL-producing E. coli from 2010 to 2015, with a high increase in this rate leading to 37% carriage (17 isolates) in 2015. The ST131 clonal group is an efficient colonizer, 35 so antibiotic selective pressure may not be essential to favour its implantation and dissemination. Of interest a very recent study found that excretion of ciprofloxacin-resistant E. coli in stool specimens of twins and their mothers (mainly ST131 E. coli) was not associated with previous antibiotic use. 36 In contrast to carriage of their counterpart, that of ST131-ESBL-producing E. coli was significantly associated with previous hospitalization, which suggests that this clonal group is actively disseminated in the hospital environment. A previous study found a higher nosocomial transmission rate of CTX-M-27-than CTX-M-15-producing ST131 strains in a rehabilitation ward. 26 Other paediatric studies reported various proportions of ST131 carriage. In 2012, a French study conducted in the south of France in childcare centres reported 44% (12 of 27) of ST131-ESBL-producing E. coli in intestinal colonization, but this finding was mainly due to local dissemination in one centre. 22 Indeed, without this local dissemination, the rate of ST131-ESBL-producing E. coli in this population was 28%, a rate similar to our study. ST131-ESBL-producing E. coli may be responsible for infections. For example, in Taiwan, up to 65% of the 111 isolates found in community-acquired urinary tract infections in children caused by ESBL-producing E. coli between 2009 and 2012 were of the ST131 group, 37 but this rate was 33% between 2008 and 2012 in a French study. 38 As in other studies, our ST131 strains harboured few virulence factors. In particular, no strains contained the PapGII adhesin. Fortunately, this adhesin is also rare in other ESBL-producing E. coli and may explain why urinary tract infections due to ESBL-producing E. coli are still rare in children without urinary tract abnormalities. Among this collection of ST131-ESBL-producing E. coli, the majority belonged to the O25b subgroup with 100% of isolates resistant to fluoroquinolones and 53% to co-trimoxazole, which is consistent with previous studies. 15, 39 Surprisingly, we also found 23% of the isolates to be O16-ST131. This O16 subset is broadly distributed, but occasionally described producing ESBL. 15, 39 Our study has some limitations. The travel countries were grouped to have a substantial number of children in each group, which decreased the information for individual countries. Only children between 6 and 24 months old were included, and no samples were taken from other family members. Finally, sampling involved a rectal swab, which only allowed for detection of the dominant clone, so we may have missed minority clones.
In conclusion, this large and timely extended multicentre study of children in a community setting identified a 2-fold increase in ESBL-E carriage in 5 years, in France. Several changes during the study period were observed: the distribution of the CTX-M variant, phylogenetic group distribution between E. coli and an increase in ST131-ESBL-producing E. coli strains. Moreover, the risk factors associated with ST131 carriage were not identical to that of non-ST131 resistant strains, which suggests that infection control measures may be adapted to the genetic background of the strain.
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